Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | Ruxolitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IP-10 | 13.0 | 83 | |
N2586 | Tofacitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | IP-10 | 11.0 | 89 | |
N2586 | IKK16 | 2.0 | uM | Adiponectin | 5 | ng/mL | 3 | IP-10 | 12.0 | 71 | |
RA2159 | IGF-I | 100 | ug/mL | 3 | IP-10 | 11.0 | 57 | ||||
RA2159 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | IP-10 | 12.0 | 79 | |
RA2159 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IP-10 | 10.0 | 61 | |
RA2159 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IP-10 | 11.5 | 60 | |
RA2159 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IP-10 | 10.0 | 77 | |
RA2159 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | IP-10 | 11.0 | 64 | |
RA2159 | 3 | IP-10 | 13.0 | 57 | |||||||
N2586 | IGF-I | 100 | ug/mL | 3 | IP-10 | 14.0 | 68 | ||||
N2586 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | IP-10 | 13.0 | 57 | |
N2586 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IP-10 | 12.0 | 79 | |
N2586 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IP-10 | 10.5 | 90 | |
N2586 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | IP-10 | 12.0 | 85 | |
N2586 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | IP-10 | 13.0 | 91 | |
N2586 | 3 | IP-10 | 10.0 | 80 | |||||||
RA2159 | EGF | 100 | ng/mL | 3 | IP-10 | 10.0 | 89 | ||||
RA2159 | PD184352 | 0.1 | uM | EGF | 100 | ng/mL | 3 | IP-10 | 9.0 | 72 | |
RA2159 | Lestaurtinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IP-10 | 10.0 | 80 | |
RA2159 | Ruxolitinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IP-10 | 11.0 | 54 | |
RA2159 | Tofacitinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | IP-10 | 9.0 | 69 | |
RA2159 | IKK16 | 2.0 | uM | EGF | 100 | ng/mL | 3 | IP-10 | 12.0 | 63 | |
RA2159 | JNK-IN-11 | 0.3 | uM | 3 | IP-10 | 10.0 | 75 | ||||
N2586 | EGF | 100 | ng/mL | 3 | IP-10 | 10.5 | 74 |